Skip to main content
SpringerLink
Log in
Book cover

New Approaches to Drug Discovery

  • Book
  • © 2016

Overview

Editors:
  1. Ulrich Nielsch

    1. Drug Discovery-Cross Indication Platform, Bayer Pharma AG, Wuppertal, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Ulrike Fuhrmann

    1. Drug Discovery-Cross Indication Platform, Bayer Pharma AG, Berlin, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Stefan Jaroch

    1. Drug Discovery-Global External Innovation & Alliances, Bayer Pharma AG, Berlin, Germany

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • In depth insights into drug discovery and early drug development
  • Latest technologies of target discovery and lead generation
  • New approaches to transfer drug candidates to clinical development

Part of the book series: Handbook of Experimental Pharmacology (HEP, volume 232)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (16 chapters)

  1. Front Matter

    Pages i-viii
    Download chapter PDF

  2. Trends in Modern Drug Discovery

    • Jörg Eder, Paul L. Herrling
    Pages 3-22

  3. Functional Genomics in Pharmaceutical Drug Discovery

    • Robert Adams, Michael Steckel, Barbara Nicke
    Pages 25-41

  4. Emerging Target Families: Intractable Targets

    • Stefan Knapp
    Pages 43-58

  5. In Vivo Target Validation Using Biological Molecules in Drug Development

    • Derek S. Sim, Katalin Kauser
    Pages 59-70

  6. High-Throughput Synthesis of Diverse Compound Collections for Lead Discovery and Optimization

    • C. Rademacher, P. H. Seeberger
    Pages 73-89

  7. Sources for Leads: Natural Products and Libraries

    • Eric F. van Herwerden, Roderich D. Süssmuth
    Pages 91-123

  8. New Compound Classes: Protein–Protein Interactions

    • C. Ottmann
    Pages 125-138

  9. Using Cheminformatics in Drug Discovery

    • Michael S. Lawless, Marvin Waldman, Robert Fraczkiewicz, Robert D. Clark
    Pages 139-168

  10. Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays

    • Gernot Langer
    Pages 171-190

  11. Translational In Vivo Models for Women’s Health: The Nonhuman Primate Endometrium—A Predictive Model for Assessing Steroid Receptor Modulators

    • Ov Daniel Slayden
    Pages 191-202

  12. Predictive In Vivo Models for Oncology

    • Diana Behrens, Jana Rolff, Jens Hoffmann
    Pages 203-221

  13. Translational In Vivo Models for Cardiovascular Diseases

    • Daniela Fliegner, Christoph Gerdes, Jörg Meding, Johannes-Peter Stasch
    Pages 223-234

  14. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety

    • Andreas Reichel, Philip Lienau
    Pages 235-260

  15. Nonclinical Safety and Toxicology

    • Claudia Stark, Thomas Steger-Hartmann
    Pages 261-283

  16. Impact of Biomarkers on Personalized Medicine

    • Patricia Carrigan, Thomas Krahn
    Pages 285-311

  17. Modeling and Simulation of In Vivo Drug Effects

    • Jörg Lippert, Rolf Burghaus, Lars Kuepfer, Bart Ploeger, Stephan Schaller, Walter Schmitt et al.
    Pages 313-329

  18. Back Matter

    Pages 331-341
    Download chapter PDF
Back to top

Keywords

About this book

This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.

Editors and Affiliations

  • Drug Discovery-Cross Indication Platform, Bayer Pharma AG, Wuppertal, Germany

    Ulrich Nielsch

  • Drug Discovery-Cross Indication Platform, Bayer Pharma AG, Berlin, Germany

    Ulrike Fuhrmann

  • Drug Discovery-Global External Innovation & Alliances, Bayer Pharma AG, Berlin, Germany

    Stefan Jaroch

About the editors

Dr. Ulrich Nielsch, Bayer Pharma AG,Wuppertal, GermanyDr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, Germany
Prof. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation